MedTrace Logo

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-06-18

No results posted yet for this study

Summary

A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects.

Conditions

  • Drug Drug Interaction

Interventions

DRUG

Fruquintinib

oral VEGFR inhibitor

DRUG

Itraconazole

a synthetic triazole antifungal agent

DRUG

Rifampin

a semisynthetic antibiotic derivative of rifamycin SV

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY

  • Hutchison Medipharma Limited

    lead INDUSTRY

Principal Investigators

  • Youngiun Kim, MD · WCCT Global Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-02
Primary Completion
2020-10-18
Completion
2020-10-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04557397 on ClinicalTrials.gov